FOP

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Retrieved on: 
Thursday, February 8, 2024
GLT, Growth, Certification, Prostate cancer, Palovarotene, Statute, Alagille syndrome, Primary biliary cholangitis, PDAC, Patient, FDA, FOP, Cabozantinib, Food, PBC, Botulinum toxin, Irinotecan, Ipsen, Phase, Acquisition, Environment, Albireo, Bank statement, Webcast, Carbon accounting, Core, Woman, Pharmaceutical industry

Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.

Key Points: 
  • Ipsen ended the year with net cash of €65.1m, driven by solid free cash-flow generation of €710.9m.
  • Ipsen anticipates four commercial launches in 2024, following regulatory decisions for Onivyde in 1L PDAC in the U.S (H1), elafibranor in second-line PBC in the U.S. (H1) and in the E.U.
  • Ipsen has set the following financial guidance for FY 2024, which excludes any impact from potential late-stage external-innovation transactions:
    Total-sales growth greater than 6.0%, at constant currency.
  • The performance shown in this announcement covers the twelve-month period to 31 December 2023 (FY 2023) and the three-month period to 31 December 2023 (Q4 2023), compared to the twelve-month period to 31 December 2022 (FY 2022) and the three-month period to 31 December 2022 (Q4 2022), respectively, unless stated otherwise.

CHICKIE'S & PETE'S AND THE CIARROCCHI FAMILY FOUNDATION RAISE $25,000 FOR THE FRATERNAL ORDER OF POLICE SURVIVORS FUND

Retrieved on: 
Wednesday, October 25, 2023
Survivor, Chickie's & Pete's, National First Responders Organization, Fraternal order, FOP, ID, Nightclub, Life insurance

PHILADELPHIA, Oct. 25, 2023 /PRNewswire/ -- Chickie's & Pete's, the renowned crab house and sports bar in Philadelphia, proudly marked National French Fry Day by hosting a $1 Crabfries day on July 13, as part of their extended week-long celebration for Crabfries Week. In collaboration with The Ciarrocchi Family Foundation, they successfully raised $25,000 for donation to The Fraternal Order of Police Survivor Fund (FOP).

Key Points: 
  • In collaboration with The Ciarrocchi Family Foundation, they successfully raised $25,000 for donation to The Fraternal Order of Police Survivor Fund (FOP).
  • Pete Ciarrocchi, Chairman & CEO of Chickie's & Pete's, stated, "We feel privileged to support exceptional organizations like the FOP Survivors Fund through our promotional initiatives.
  • "We are very grateful for the ongoing support of Chickie's & Pete's and the Ciarrocchi Family Foundation," said John McNesby, President of the Fraternal Order of Police Lodge 5.
  • Thanks to the overwhelming success of this event over the years, Chickie's & Pete's has now donated over $150,000 to the FOP Survivors Fund.

Valor Sports & Entertainment, Inc Announces Landmark Collaboration with the Florida State (FOP) Fraternal Order of Police

Retrieved on: 
Tuesday, October 3, 2023
Entertainment, Sports, General Entertainment, Extreme Sports, Boxing, Martial Arts, General Sports, Eastern Florida State College, Partnership, Shamrock, Law enforcement, Fraternal order, Woman, Multimedia, History, NO, FOP, UNF, CIRCLE, Courage, Social media, Police, Nightclub

Valor Sports & Entertainment, Inc., a leading name in the combat sports industry, is thrilled to announce its groundbreaking collaboration with the Florida State (FOP) Fraternal Order of Police.

Key Points: 
  • Valor Sports & Entertainment, Inc., a leading name in the combat sports industry, is thrilled to announce its groundbreaking collaboration with the Florida State (FOP) Fraternal Order of Police.
  • (Photo: Business Wire)
    The Florida State (FOP), with its rich history and dedication to serving both officers and the community, finds a synergistic partner in Valor Sports Inc.
  • “Valor is truly committed to this partnership, and working closely with the Florida State FOP will be ongoing.
  • "The Florida State Fraternal Order of Police and our 25,000 members are truly thankful for the partnership with Valor Sports & Entertainment and Valor Bare Knuckle.

EQS-News: Eleving Group S.A.: Eleving Group commences Exchange Offer for Bondholders of Mogo AS 2021/2024 bonds

Retrieved on: 
Tuesday, September 26, 2023
Financial adviser, Senior, Agios Ioannis Rentis, Settlement date, Commission, The Elevation Group, CIS, Exchange, Fitch, Sebo, EUR, EBITDA, FOP, RC Kredo-63, FX, Commission de Surveillance du Secteur Financier, Millicom, ISIN, Frankfurt Stock Exchange, Fitch Ratings, Growth, General Standard, National Association of Personal Financial Advisors, News, CSSF, Security (finance), Cryptocurrency, Financial services, Baltic, Central Europe

Exchange offer period for bondholders of Mogo AS unsecured bonds with ISIN code LV0000802452 from September 26 to October 13, 2023, 14:00 EET.

Key Points: 
  • Exchange offer period for bondholders of Mogo AS unsecured bonds with ISIN code LV0000802452 from September 26 to October 13, 2023, 14:00 EET.
  • Bondholders of Mogo AS unsecured bonds are encouraged to reach out to their depository banks, Signet Bank or Eleving Group for further information.
  • The exchange offer period of Eleving Group's new bonds is set to last from September 26 until October 13, 2023.
  • All existing holders of Mogo AS unsecured bonds (ISIN LV0000802452) are offered the opportunity to exchange their existing bonds for new Eleving Group senior secured and guaranteed bonds with a higher coupon rate.

Retinoic Acid Receptor Agonists Drug Pipeline Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 14, 2023
Health, Pharmaceutical, MO, Retinoic acid, Therapy, Fibrodysplasia ossificans progressiva, Retinoic acid receptor, Ipsen, Clinical trial, Cancer, Vitamin A, RARS, II, Telecanthus, Discovery, Acquisition, FOP, Patient, Mergers and acquisitions, III, News, RAR, Natural gas, Pharmaceutical industry, Fine chemical

The "Retinoic acid receptor agonists - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Retinoic acid receptor agonists - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The report serves as an exhaustive source of insights into the landscape of Retinoic Acid Receptor (RARs) Agonist pipeline, encompassing over 15 companies and 15 pipeline drugs.
  • The ongoing development of therapies revolves around innovative strategies, aiming to address the intricacies of Retinoic Acid Receptor (RARs) Agonist.
  • Retinoic Acid Receptor (RARs) Agonist: Therapeutic Assessment
    This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report.

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

Retrieved on: 
Thursday, July 27, 2023
IPN, Heart, Cholestatic pruritus, Maintenance, CHC, FY, Ascending cholangitis, Civil service commission, ADR, Prescription Drug User Fee Act, Fibrodysplasia ossificans progressiva, Ursodeoxycholic acid, Account, Ipsen, Galderma, Bank statement, Oxaliplatin, COMP, Rare disease, New Drug Application, European Directive on Traditional Herbal Medicinal Products, Research, Committee, EMA, ICC, Primary biliary cholangitis, Report, FOP, Patient, Committee for Medicinal Products for Human Use, PDUFA, Webcast, Consumer, Growth, Ageing, Alagille syndrome, Indoor Living, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Food, European Commission, Safety, CHMP, Pharmaceutical industry, Medical device, Cryptocurrency, ALGS, Oncology, Neuroscience, Odevixibat, Euronext

The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance.

Key Points: 
  • The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance.
  • The Company’s auditors performed a limited review of the H1 2023 condensed consolidated financial statements.
  • Ipsen intends to publish its year-to-date and third-quarter sales update on 26 October 2023.
  • The performance shown in this announcement covers the six-month period to 30 June 2023 (H1 2023) and the three-month period to 30 June 2023 (Q2 2023), compared to six-month period to 30 June 2022 (H1 2022) and the three-month period to 30 June 2022 (Q2 2022), respectively, unless stated otherwise.

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

Retrieved on: 
Wednesday, July 19, 2023
IPN, Skeleton, Civil service commission, ADR, Fibrodysplasia ossificans progressiva, Ipsen, Clinical trial, Committee on Herbal Medicinal Products, Necker–Enfants Malades Hospital, Life expectancy, Committee, Research and development, Development, European Commission, FOP, Patient, MOVE, Arrest, Joint, Diagnosis, Committee for Medicinal Products for Human Use, Heterotopic ossification, Death, Disease, Caregiver, CHMP, Pharmaceutical industry, Nursing, Euronext, Research

Palovarotene is the first treatment to be submitted anywhere in the world for regulatory approval for FOP, an ultra-rare disease with approximately 900 known cases worldwide.

Key Points: 
  • Palovarotene is the first treatment to be submitted anywhere in the world for regulatory approval for FOP, an ultra-rare disease with approximately 900 known cases worldwide.
  • “We worked tirelessly to bring a greatly needed treatment option to patients living with FOP in the E.U.,” said Howard Mayer, Executive Vice President and Head of Research and Development for Ipsen.
  • We are therefore disappointed that the European Commission decided not to approve this treatment for patients with FOP in Europe.
  • This included MOVE, the first and largest Phase III clinical trial for FOP, a condition that causes abnormal bone growth.

CHICKIE'S & PETE'S ANNOUNCES WEEK-LONG CELEBRATION FOR NATIONAL CRABFRIES® DAY FROM JULY 10 - 14

Retrieved on: 
Wednesday, July 12, 2023
Police Academy 2: Their First Assignment, Partnership, Travel, Chickie's & Pete's, Fraternal order, Heroes, FOP, Survivor, Pete, Life insurance, Fair, Nightclub, Chickie

PHILADELPHIA, July 12, 2023 /PRNewswire/ -- Philly's favorite sports bar and restaurant, Chickie's & Pete's, will be taking their annual celebration of Crabfries to new heights this year as they introduce Crabfries Week from Monday, July 10 through July 13, 2023. As is their 10-year tradition, all sales from $1 Crabfries orders on Thursday, July 13th will be donated to The Fraternal Order of Police Survivor Fund. In addition, the Chickie's and Pete's Crabfries Express Food Truck will travel to select Philadelphia Police Districts and the Police Academy to deliver free lunch to Philadelphia police officers.

Key Points: 
  • In addition, the Chickie's and Pete's Crabfries Express Food Truck will travel to select Philadelphia Police Districts and the Police Academy to deliver free lunch to Philadelphia police officers.
  • Since its inception, Chickie's & Pete's has donated over $150,000 to the FOP Survivors Fund thanks to the monumental success of their event.
  • This man and his team live their lives by being a part of our community every day and supporting our officers day in and day out."
  • Chickie's & Pete's has donated over $150,000 to the FOP Survivors Fund thanks to the monumental success of their event.

Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva

Retrieved on: 
Thursday, June 29, 2023
IPN, HO, Priority review, Oral medicine, Disease, Fibrodysplasia ossificans progressiva, ADR, Ipsen, Ligament, New Drug Application, NDA, Life expectancy, Development, Protein, FOP, Patient, Palliative care, Phase, FDA, Heterotopic ossification, Death, Regulation of tobacco by the U.S. Food and Drug Administration, Tendon, Food, Pharmaceutical industry, Palovarotene, Euronext, Research

The FDA is currently reviewing the New Drug Application (NDA) for palovarotene with a decision anticipated by August 16, 2023.

Key Points: 
  • The FDA is currently reviewing the New Drug Application (NDA) for palovarotene with a decision anticipated by August 16, 2023.
  • If approved, palovarotene will be the first treatment in the U.S. for FOP.
  • “We are pleased with the outcome today and believe that the vote of the FDA advisory committee conveys the potential of palovarotene in helping manage the severe impacts of FOP.
  • Palovarotene is currently authorized for use in appropriate patients in Canada and United Arab Emirates where it is marketed as SohonosTM (palovarotene capsules).6

DiCello Levitt: Eight Akron Police Officers Who Killed Jayland Walker Used Excessive Force, Police Department Has Fostered a Culture of Violence and Racism, According to New Federal Lawsuit

Retrieved on: 
Friday, June 16, 2023
Professional Services, Public Policy, Government, Law Enforcement, Emergency Services, Consumer, Women, Legal, Men, Violence, Human, Fraternal Order of Police, Crime, City of Akron v. Akron Center for Reproductive Health, Culture, First Congregational Church, Fraternal order, EDT, Complaint, Killing of Jayland Walker, First Congregational Church (Akron, Ohio), District court, City, Ohio Bureau of Criminal Investigation, FOP, Police, Eastern Division, Racism, Trauma, Akron Police Department, Internal, John Davis (U.S. district court judge), Family, PBS, Drug, Private investigator

It also notes that the violent behavior of the eight shooters was made possible by a culture of violence and racism within the Akron Police Department.

Key Points: 
  • It also notes that the violent behavior of the eight shooters was made possible by a culture of violence and racism within the Akron Police Department.
  • In addition to the City of Akron and the officers involved in the shooting, the lawsuit also names as defendants Akron Mayor Daniel Horrigan and Chief of Police Stephen Mylett.
  • The family’s attorneys, Bobby DiCello and Kenneth Abbarno of DiCello Levitt will be joined by Jayland Walker’s mother, Pam Walker, his sister, Jada Walker, and Akron community leader, Pastor Robert DeJournett.
  • On June 27, 2022, eight Akron police officers pursued Walker for a minor traffic violation.